Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma

10 Oct 2014

Abstract excerpt

Multiparameter flow cytometry (MFC) and allele-specific oligonucleotide real-time quantitative PCR (ASO RQ-PCR) are the two most sensitive methods to detect minimal residual disease (MRD) in multiple myeloma (MM). We compared these methods in 129 paired post-therapy samples from 22 unselected, consecutive MM patients in complete/near complete remission. Appropriate immunophenotypic and ASO RQ-PCR-MRD targets...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Monoclonal and Polyclonal Antibodies Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25303369
DOI: 10.1038/bcj.2014.69

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myelomaPMID 25303369Read ↗

Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.Semantic proximity Read ↗

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.Semantic proximity Read ↗

Molecular detection of minimal residual disease in multiple myelomaSemantic proximity Read ↗

Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.Semantic proximity Read ↗

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaSemantic proximity Read ↗

Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐<scp>PCR</scp>of immunoglobulin genes in multiple myeloma. Results from a<scp>GEM</scp>/<scp>PETHEMA</scp>studySemantic proximity Read ↗

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future PerspectivesSemantic proximity Read ↗

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useSemantic proximity Read ↗

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaSemantic proximity Read ↗

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.Semantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.